Phytocannabinoids and schizophrenia: Focus on adolescence as a
critical window of enhanced vulnerability and opportunity for
treatment

J 2021

Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment

ŠTARK, Tibor, S. DI MARTINO, F. DRAGO, C. T. WOTJAK, V. MICALE et. al.

Basic information

Original name

Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment

Authors

ŠTARK, Tibor (703 Slovakia, belonging to the institution), S. DI MARTINO, F. DRAGO, C. T. WOTJAK and V. MICALE (guarantor)

Edition

Pharmacological Research, London, ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021, 1043-6618

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 10.334

RIV identification code

RIV/00216224:14110/21:00124165

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.phrs.2021.105938

UT WoS

000724713300004

Keywords in English

THC; Cannabidiol; Adolescence; Schizophrenia; Animal model; Neurodevelopment

Abstract

V originále

The recent shift in socio-political debates and growing liberalization of Cannabis use across the globe has raised concern regarding its impact on vulnerable populations such as adolescents. Concurrent with declining perception of Cannabis harms, more adolescents are using it daily in several countries and consuming marijuana strains with high content of psychotropic delta (9)-tetrahydrocannabinol (THC). These dual, related trends seem to facilitate the development of compromised social and cognitive performance at adulthood, which are described in preclinical and human studies. Cannabis exerts its effects via altering signalling within the endocannabinoid system (ECS), which modulates the stress circuitry during the neurodevelopment. In this context early interventions appear to circumvent the emergence of adult neurodevelopmental deficits. Accordingly, Cannabis sativa second-most abundant compound, cannabidiol (CBD), emerges as a potential therapeutic agent to treat neuropsychiatric disorders. We first focus on human and preclinical studies on the long-term effects induced by adolescent THC exposure as a "critical window" of enhanced neurophysiological vulnerability, which could be involved in the pathophysiology of schizophrenia and related primary psychotic disorders. Then, we focus on adolescence as a "window of opportunity" for early pharmacological treatment, as novel risk reduction strategy for neurodevelopmental disorders. Thus, we review current preclinical and clinical evidence regarding the efficacy of CBD in terms of positive, negative and cognitive symptoms treatment, safety profile, and molecular targets.

Links

MUNI/A/1249/2020, interní kód MU

Name: Základní výzkum v oblasti farmakokinetiky, neurobiologie závislostí a aplikovaný výzkum v oblasti personalizované farmakoterapie v onkologii (Acronym: SV_Farmakologie2021)

Investor: Masaryk University

3SGA5789, interní kód MU

Name: PRECIPITATION OF SCHIZOPHRENIA-LIKE PHENOTYPE BY PRENATAL INFLUENCES: ASSESSING THE ROLE OF THE ENDOCANNABINOID SYSTEM (Acronym: ncRNAPain)

Investor: South-Moravian Region, Incoming grants

Citovat

ŠTARK, Tibor, S. DI MARTINO, F. DRAGO, C. T. WOTJAK and V. MICALE. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacological Research. London: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021, vol. 174, December 2021, p. 1-15. ISSN 1043-6618. Available from: https://dx.doi.org/10.1016/j.phrs.2021.105938.

@article{1834411,
   author = {Štark, Tibor and Di Martino, S. and Drago, F. and Wotjak, C. T. and Micale, V.},
   article_location = {London},
   article_number = {December 2021},
   doi = {http://dx.doi.org/10.1016/j.phrs.2021.105938},
   keywords = {THC; Cannabidiol; Adolescence; Schizophrenia; Animal model; Neurodevelopment},
   language = {eng},
   issn = {1043-6618},
   journal = {Pharmacological Research},
   title = {Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment},
   url = {https://www.sciencedirect.com/science/article/pii/S1043661821005223?via%3Dihub},
   volume = {174},
   year = {2021}
}

TY  - JOUR
ID  - 1834411
AU  - Štark, Tibor - Di Martino, S. - Drago, F. - Wotjak, C. T. - Micale, V.
PY  - 2021
TI  - Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
JF  - Pharmacological Research
VL  - 174
IS  - December 2021
SP  - 1-15
EP  - 1-15
PB  - ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
SN  - 10436618
KW  - THC
KW  - Cannabidiol
KW  - Adolescence
KW  - Schizophrenia
KW  - Animal model
KW  - Neurodevelopment
UR  - https://www.sciencedirect.com/science/article/pii/S1043661821005223?via%3Dihub
N2  - The recent shift in socio-political debates and growing liberalization of Cannabis use across the globe has raised concern regarding its impact on vulnerable populations such as adolescents. Concurrent with declining perception of Cannabis harms, more adolescents are using it daily in several countries and consuming marijuana strains with high content of psychotropic delta (9)-tetrahydrocannabinol (THC). These dual, related trends seem to facilitate the development of compromised social and cognitive performance at adulthood, which are described in preclinical and human studies. Cannabis exerts its effects via altering signalling within the endocannabinoid system (ECS), which modulates the stress circuitry during the neurodevelopment. In this context early interventions appear to circumvent the emergence of adult neurodevelopmental deficits. Accordingly, Cannabis sativa second-most abundant compound, cannabidiol (CBD), emerges as a potential therapeutic agent to treat neuropsychiatric disorders. We first focus on human and preclinical studies on the long-term effects induced by adolescent THC exposure as a "critical window" of enhanced neurophysiological vulnerability, which could be involved in the pathophysiology of schizophrenia and related primary psychotic disorders. Then, we focus on adolescence as a "window of opportunity" for early pharmacological treatment, as novel risk reduction strategy for neurodevelopmental disorders. Thus, we review current preclinical and clinical evidence regarding the efficacy of CBD in terms of positive, negative and cognitive symptoms treatment, safety profile, and molecular targets.
ER  -

ŠTARK, Tibor, S. DI MARTINO, F. DRAGO, C. T. WOTJAK and V. MICALE. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. \textit{Pharmacological Research}. London: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021, vol.~174, December 2021, p.~1-15. ISSN~1043-6618. Available from: https://dx.doi.org/10.1016/j.phrs.2021.105938.

Detailed Information on Publication Record